Cargando…

Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era

PURPOSE OF REVIEW: To identify and address the challenges associated with the care of ACS patients during the coronavirus 2019 pandemic. RECENT FINDINGS: The COVID-19 pandemic has had a considerable global impact with over 2.0 million deaths worldwide so far. There has been considerable evidence sug...

Descripción completa

Detalles Bibliográficos
Autores principales: Borgaonkar, Sanket, Hahn, Joshua, Daher, Marilyne, Kayani, Waleed, Jneid, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102148/
https://www.ncbi.nlm.nih.gov/pubmed/33961122
http://dx.doi.org/10.1007/s11886-021-01501-7
_version_ 1783689072493985792
author Borgaonkar, Sanket
Hahn, Joshua
Daher, Marilyne
Kayani, Waleed
Jneid, Hani
author_facet Borgaonkar, Sanket
Hahn, Joshua
Daher, Marilyne
Kayani, Waleed
Jneid, Hani
author_sort Borgaonkar, Sanket
collection PubMed
description PURPOSE OF REVIEW: To identify and address the challenges associated with the care of ACS patients during the coronavirus 2019 pandemic. RECENT FINDINGS: The COVID-19 pandemic has had a considerable global impact with over 2.0 million deaths worldwide so far. There has been considerable evidence suggesting that COVID-19 increases the risk of acute coronary syndromes (ACS). SUMMARY: We propose characterizing ACS patients into 3 distinct categories to better assist in appropriate triage and management: critically ill patients, non-critically ill ST elevation myocardial infarction (STEMI) patients, and non-critically ill non-ST elevation myocardial infarction (NSTEMI)/unstable angina (UA) patients. We thoroughly review treatments strategies, management considerations, and current consensus statements for the care of COVID-19 patients with ACS. As we continue to gain more experience with management of COVID-19 in ACS patients and as health-care workers and patients continue to get vaccinated, we must continue to adapt our strategies to treat this high-risk group of patients.
format Online
Article
Text
id pubmed-8102148
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-81021482021-05-07 Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era Borgaonkar, Sanket Hahn, Joshua Daher, Marilyne Kayani, Waleed Jneid, Hani Curr Cardiol Rep Management of Acute Coronary Syndromes (H Jneid, Section Editor) PURPOSE OF REVIEW: To identify and address the challenges associated with the care of ACS patients during the coronavirus 2019 pandemic. RECENT FINDINGS: The COVID-19 pandemic has had a considerable global impact with over 2.0 million deaths worldwide so far. There has been considerable evidence suggesting that COVID-19 increases the risk of acute coronary syndromes (ACS). SUMMARY: We propose characterizing ACS patients into 3 distinct categories to better assist in appropriate triage and management: critically ill patients, non-critically ill ST elevation myocardial infarction (STEMI) patients, and non-critically ill non-ST elevation myocardial infarction (NSTEMI)/unstable angina (UA) patients. We thoroughly review treatments strategies, management considerations, and current consensus statements for the care of COVID-19 patients with ACS. As we continue to gain more experience with management of COVID-19 in ACS patients and as health-care workers and patients continue to get vaccinated, we must continue to adapt our strategies to treat this high-risk group of patients. Springer US 2021-05-07 2021 /pmc/articles/PMC8102148/ /pubmed/33961122 http://dx.doi.org/10.1007/s11886-021-01501-7 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Management of Acute Coronary Syndromes (H Jneid, Section Editor)
Borgaonkar, Sanket
Hahn, Joshua
Daher, Marilyne
Kayani, Waleed
Jneid, Hani
Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era
title Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era
title_full Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era
title_fullStr Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era
title_full_unstemmed Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era
title_short Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era
title_sort invasive therapies for acute coronary syndromes in the covid-19 era
topic Management of Acute Coronary Syndromes (H Jneid, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102148/
https://www.ncbi.nlm.nih.gov/pubmed/33961122
http://dx.doi.org/10.1007/s11886-021-01501-7
work_keys_str_mv AT borgaonkarsanket invasivetherapiesforacutecoronarysyndromesinthecovid19era
AT hahnjoshua invasivetherapiesforacutecoronarysyndromesinthecovid19era
AT dahermarilyne invasivetherapiesforacutecoronarysyndromesinthecovid19era
AT kayaniwaleed invasivetherapiesforacutecoronarysyndromesinthecovid19era
AT jneidhani invasivetherapiesforacutecoronarysyndromesinthecovid19era